The FDA has approved an Erbitux label update to include additional survival data. ImClone and Bristol-Myers Squibb, who make the drug, announced back in January [1] that research indicated Erbitux proved effective as a front-line therapy against colon cancer. Release [2]
Links:
[1] http://www.fiercebiotech.com/story/erbitux-data-backs-use-as-front-line-therapy/2007-01-10
[2] http://www.fiercebiotech.com/press-releases/press-release-imclone-systems-says-broader-us-label-erbitux-colorectal-cancer-drug